Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment
Ended Awarded
- Contract number
- HT009025FG0820120
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $14,435
Award facts
- Contract value 100% obligated
- $14,434.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- Q517 Pharmacy Services
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Sterling, VA, USA
Award details come from SAM.gov/FPDS.
About this award
Sofie CO., operating under the trade name IBA Molecular, received a federal contract award from the Defense Health Agency on August 20, 2025, for the provision of radiopharmaceuticals needed to treat prostate cancer patients with metastatic lesions following definitive treatment. This BPA (Blanket Purchase Agreement) call, valued at $14,434.88 on a firm fixed-price basis, will be performed in Sterling, Virginia, with completion targeted for September 30, 2025. The contract carries no set-aside designation, reflecting Sofie CO.'s competitive standing as a specialized supplier in the federal radiopharmaceutical market. As a subsidiary of Sofie Biosciences, Inc., the company specializes in molecular diagnostics and PET imaging agents, and this award represents a task order under one of the company's existing Defense Health Agency BPAs for pharmaceutical supplies and radiopharmaceuticals.
This award supports the Department of Defense's medical treatment capabilities by enabling the provision of specialized diagnostic imaging products for military personnel and beneficiaries. Sofie CO. has established itself as a key federal supplier through multiple contract vehicles with the VA and Defense Health Agency, including contracts for PYLARIFY (F-18 DCFPYL) and other PET imaging agents used in cancer detection and neurological imaging. The relatively modest task order value of approximately $14.4K is consistent with the company's portfolio of routine procurement orders under its larger blanket purchase agreements, which collectively exceed $13 million across multiple federal healthcare programs.
Quick answers
Who was awarded contract HT009025FG0820120?
HT009025FG0820120 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on August 20, 2025.
How much is contract HT009025FG0820120 worth?
The government has obligated $14,435 on HT009025FG0820120.
Is contract HT009025FG0820120 an order under another contract?
Yes. HT009025FG0820120 is a BPA call under HT001424A0002, a blanket purchase agreement.
Was contract HT009025FG0820120 competed?
The extent of competition for HT009025FG0820120 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award